“The results presented today demonstrate that IRX-2, a primary cell-derived biologic, drives intratumoral immune infiltration of T cells, B cells and dendritic cells, promoting their activation. “This increase
According to the agreement, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads which will be licensed exclusively
The collaboration will bring together Gubra’s expertise in the design, synthesis, characterization and in in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the development of
The loan agreement is operated under the European Fund of Strategic Investments ("EFSI"). EFSI is an essential pillar of the Investment Plan for Europe ("IPE"), under which the
The Phase 2 trial achieved its primary endpoint prior to the completion of enrollment The trial protocol requires four confirmed, partial responses, per RECIST 1.1 criteria, out of
Upon exercise of this option and transition of the programme, GSK will assume responsibility for all development, manufacturing and commercialisation activities for the asset. Adaptimmune will receive up
The collaboration will seek to identify and develop Bicycles to treat rare blood disorders. Bicycles are a new therapeutic modality that combine attributes of antibodies, small molecules and
PATH also announced that several global experts in vaccine development and introduction have joined PATH CVIA to advance these critical vaccine efforts. “We are excited to continue our
Noctiva is a proprietary low-dose formulation of desmopressin acetate administered through a patent-protected intranasal delivery system. It is the first and only product approved by the U.S. Food
Glioblastoma multiforme and anaplastic astrocytoma are the most common and most severe forms of non-metastatic brain cancer. According to the Central Brain Tumor Registry of the United States,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.